Status:
COMPLETED
Yliver as a Test to Early Diagnose HCC
Lead Sponsor:
Corporacion Parc Tauli
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-99 years
Brief Summary
Liver cancer (HCC) is the second cause of death related to cancer worldwide, with about 750,000 deaths from this cause in 2012. Although the early diagnosis of liver cancer increases the available tre...
Eligibility Criteria
Inclusion
- EASL Clinical Practice Guidelines \& Practice Guidance by the American Association for the Study of Liver Diseases for diagnosis of HCC, liver cirrhosis, chronic hepatitis without cirrhosis
Exclusion
- Age under 18 years
- Very advanced disease (patient in a terminal state that is not indicated analytical determinations).
- Hepatic encephalopathy that prevents the correct understanding of informed consent.
- Refusal to carry out the determination or to sign the informed consent.
- Patients affected by another neoplastic disease
Key Trial Info
Start Date :
December 27 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2020
Estimated Enrollment :
190 Patients enrolled
Trial Details
Trial ID
NCT03767764
Start Date
December 27 2018
End Date
September 1 2020
Last Update
July 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Corporacion Parc Taulí
Sabadell, Barcelona, Spain, 08208